AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Anastrozole was effective and well tolerated for adjuvant treatment of early, hormone-sensitive breast cancer in postmenopausal patients in a large, randomized trial.
These findings suggest that anastrozole is another treatment option for postmenopausal patients with newly diagnosed, early hormone-responsive breast cancer.
Ongoing studies are evaluating potential benefits of switching patients from tamoxifen to anastrazole, according to Dr. J. Houghton and colleagues of the Arimidex, Tamoxifen Alone or in Combination (ATAC) Trialists' Group, London.
The trial involved 9,366 patients with invasive, operable breast cancer who had completed primary therapy and were randomized to receive anastrazole alone (3,125 patients), tamoxifen alone (3,116 patients), or a combination of the two (3,125 patients).
After a median of 33 months follow-up, ...
Source: HighBeam Research, Anastrozole effective for newly diagnosed breast cancer. (Adjunctive...